counter statistics
World’s first mass malaria vaccine

World’s first mass malaria vaccine

The World Health Organization (WHO) has recommended widespread use of the RTS,S/AS01 (Mosquirix) World’s first mass malaria vaccine rollout could prevent thousands of children dying vaccine in young children who are most at risk of malaria in Africa. Mosquitoes spread the parasite Plasmodium falciparum from person to person when they bite. So until now, our fight against malaria has involved using mosquito nets to avoid being bitten and spraying insecticide to kill mosquitoes. Then there are drugs to prevent or treat malaria infection.

However, the parasite has developed resistance to antimalarial drugs and mosquitoes have developed  resistance to insecticides. Nevertheless existing control measures have resulted in a significant decrease in the number of malaria deaths since 2000. In recent years, however, progress has stalled. In 2019, malaria infection resulted in 409,000 deaths around the world, mostly in children under five years old, and 229 million new malaria cases. So we need extra tools, such as an effective malaria vaccine, if we are to control the disease globally. WHO’s recommendation to roll out the Mosquirix vaccine to children at high risk of infection with P. falciparum, which is widespread in Africa, is an important step towards controlling the deadliest of human malaria parasites.

What did the WHO recommend?
The WHO recommended four doses of the vaccine in children from five months old. This recommendation follows recent results from a pilot program in Ghana, Kenya and Malawi, involving vaccinating more than 800,000 children since 2019. The program showed delivering the vaccine is feasible and cost-effective in high-risk areas. It also increased the number of children (to more than 90%) who have access to at least one intervention to prevent malaria.

The vaccine has a good safety profile and reduces cases of clinical and severe malaria, which can be deadly.

What do we know about the vaccine?
Mosquirix is a “subunit” vaccine. The vaccine works mainly by stimulating the body to make antibodies against the parasite, neutralising it, and preventing it from entering liver cells. These are the first cells the parasite invades when it enters the body. The vaccine also works by helping to mount an inflammatory response, when a different part of the immune system responds.

The vaccine isn’t perfect
The level of protection the vaccine provides isn’t ideal. Protection varies with the age of the child when vaccinated, with less protection for young infants compared with older children. In the older children (5-17 months old), this averaged at about 36% protection against developing clinical malaria over a four-year period.

Protective immunity also decreases rapidly over time. This means regular booster doses will be required. Alternative immunisation schedules are also being evaluated. Yet, the vaccine can still make a significant contribution to malaria control when used in areas of high malaria risk and with other control measures. One modelling study estimated that in sub-Saharan Africa, Mosquirix could prevent up to 5.2 million cases of malaria and 27,000 deaths in young children each year.

Why has it taken so long to get here?
Developing a malaria vaccine is challenging. Technically, it is difficult to develop a vaccine against a parasite that lives in two hosts (mosquitoes and humans).

There has also been limited interest by pharmaceutical companies in developing a malaria vaccine .

Although travellers would benefit from a vaccine when travelling to affected countries, the people who most need a malaria vaccine live in some of the world’s poorest countries. So there is little financial incentive to develop a vaccine. This time-frame is not long considering both the antigen design and the adjuvant system were novel. The Bill & Melinda Gates Foundation and GSK supported further development, including evaluating the vaccine in clinical trials. Over three decades, they invested around US$700,000 million to develop the vaccine.

What next?
Preliminary results for a new modified vaccine, called R21, are encouraging. Other malaria vaccines in development include whole parasite vaccines.  These involve injecting long-lasting antibodies to prevent malaria infection.

A whole new set of challenges In the meantime, WHO’s recommendation presents a new set of challenges. Malaria-affected countries must decide whether to include Mosquirix as part of their national malaria control strategy.

Related Posts